Fluorescence polarization immunoassay: Does it always represent a reliable method to monitor treatment with teicoplanin? Comparison with data obtained by high-performance liquid chromatography

International Journal of Pharmaceutics

Volumn 146, Issue 2, 1997, Pages 167-174

  Bourget, P ^a   Lesne Hulin, A ^d   Sertin, A ^d   Maillot, A ^d   Alaya, M ^b   Martin, C ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

^c HÔPITAL NORD   (France)

^d NONE

Author keywords

Fluorescence polarization; HPLC; Intensive care unit patients; Teicoplanin

Indexed keywords

TEICOPLANIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031039967     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(96)04797-7     Document Type: Article

References (16)

1. Adamczyk M., Fishpaugh J., Harrington C., Hartter D., Johnson D. and Vanderbilt A., Immunoassay reagents for psychoactive drugs. Part 2. The method for the development of antibodies specific to imipramine and desipramine. J. Immuno. Methods. (1993) 163-187.
2. Antibiogram Committee of the French Society for Microbiology. Pathol. Biol., 44 (1996) I-VIII.
3. Awni W.M., St Peter W.L., Guay D.R.P., Kenny M.T. and Matzke G.R., Teicoplanin measurement in patients with renal failure: comparison of fluorescence polarization immunoassay, microbiological assay and high-performance liquid chromatographic assay. Ther. Drug Monit., 13 (1991) 511-517.
4. Bland J.M. and Altman D.G,. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 19 (1986) 908-909.
5. Brogden R.N. and Peters D.H., Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 47 (1994) 823-854.
6. Campoli-Richards D.M., Brodgen R.N. and Faulds D., Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs, 40 (1990) 449-486.
7. Davey P.G. and Williams A.H., A review of the safety profile of teicoplanin. J. Antimicrob. Chemother., 21 (1991) 69-73.
8. Diem K. and Seldrup J., In: Lentner C. (Ed.), Geigy Scientific Tables, Statistical Tables, Basle, 1982, pp. 210-212.
9. Jehl F., Monteil H. and Tarral A., HPLC quantitation of the six main components of teicoplanin in biological fluids. J. Antimicrob. Chemother., 21 (1988) 53-59.
10. Jolley M.E., Stroupe S.D., Wang C.H., Panas H.S., Keegan C.L., Schmidt R.L. and Schwenzer K.S., Fluorescence polarization immunoassay I. Monitoring aminoglycoside antibiotics in serum and plasma. Clin. Chem., 27 (1981) 1190-1197.
11. Kropec A. and Daschner F.D., Penetration into tissues of various drugs active against Gram-positive bacteria. J. Antimicrob. Chemother., 27 (1991) 9-15.
12. Popelka S., Miller D., Holen J. and Kelso D., Fluorescence polarization immunoassay II. Analyzer for rapid, precise measurement of fluorescence polarization with use of disposable cuvettes. Clin. Chem., 27 (1981) 1198.
13. Reynolds P.E., Inhibitors of bacterial wall synthesis. The Scientific Basis of Antimicrobial Chemotherapy. Greenwood Eds, Cambridge. (1985). pp. 13-40.
14. Rowland M., Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet., 18 (1990) 184-209.
15. St. Peter W.L., Awni W.M., Matzke G.R. and Thompson G.A., Multiple dose teicoplanin pharmacokinetics in infected hemodialysis patients utilizing a new fluorescence polarization immunoassay. 11th Annual Meeting of the American College of Clinical Pharmacy, 10 (1990) 239.
16. TDx FLx Teicoplanin Assay, BMD Diagnostic, Marne-la-Vallée, France.